Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis
{{output}}
Background: Biologics are recommended for use in patients with psoriatic arthritis (PsA) after the failure of conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs). However, compared to csDMARDs, biologics are s... ...
